AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection
Jun-Min Song1, Min Lu, Fang-Fang Liu
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Hepatic, Biliary, and Pancreatic Surgery Unit I, Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fu Cheng Road, Beijing, 100142, China.
Background:
Amplified in breast cancer 1 (AIB1) has been shown to promote growth and invasion in several types of human cancers and to have a prognostic role in some of cancers. However, its prognostic significance in hepatocellular carcinoma (HCC) remains unknown. This study aimed to address the issue.
Methods:
Immunohistochemical staining of AIB1 was performed for HCC and paired paratumorous liver (PTL) tissues from 139 patients. Associations between AIB1 expression with clinicopathological variables and patient survival were evaluated.
Results:
The expression rate of AIB1 was significantly higher in HCC (71/139, 51.1%) than in PTL tissues (1/139, 0.72%, P < 0.001). AIB1 expression in HCC was significantly associated with serum α-fetoprotein levels (P = 0.001) and Edmondson-Steiner grade (P = 0.038). Higher AIB1 expression in HCC was associated with shorter cumulative overall survival of the patients. Multivariate Cox regression analysis revealed that AIB1 was of independent prognostic significance for HCC.
Conclusions:
AIB1 is independently associated with poor prognosis of HCC.
